Body Mass Index (BMI) is an imperfect tool for risk assessment. A patient can have a normal BMI but a high percentage of body fat—a condition called "normal weight obesity." This is a significant, yet often overlooked, risk factor for both breast cancer development and recurrence.

Constant messaging about diet and lifestyle as cancer causes fosters patient guilt. A more effective public health approach would de-emphasize these inconclusive factors and instead invest in predictive AI models that assess individual risk based on concrete factors like breast density.

Despite low individual recurrence rates, the vast number of women diagnosed with early-stage breast cancer means they account for most deaths. The annual proportion of deaths from stage 2 disease rose from 26% to 40%, while stage 1 accounts for another 23%. This highlights the need for better monitoring, like ctDNA, in this population.

A subset of breast cancers (10-15%) are "non-shedders," meaning they don't release detectable ctDNA. Patients with these tumors have excellent outcomes regardless of chemotherapy, suggesting that surgery alone might be a sufficient and less toxic treatment for this specific group.

A positive genetic test does not automatically mandate the most aggressive surgery. For older patients, such as a 70-year-old with a new breast cancer and BRCA mutation, the clinical context—life expectancy, overall health—is paramount. A "knee-jerk" bilateral mastectomy may be overtreatment in such cases.

Treating genetic testing as a "magic" or specialized service reserved for counselors has caused a 30-year disservice to patients. This fear and hesitation has led to an estimated 38,000 missed opportunities annually to identify hereditary risk, resulting in larger cancers, harsher treatments, and more deaths.

For BRCA mutation carriers without cancer, the choice is not just about survival. While prophylactic mastectomy prevents most cancers, intensive screening with mammography and MRI detects cancers early enough that mortality rates are not significantly different. This allows patients to choose based on personal risk tolerance.

Dr. Wander notes a strong clinical correlation: a BRCA mutation found on a somatic NGS test with a ~30-60% allelic frequency is very likely germline. However, this cannot replace a dedicated, CLIA-approved germline test for formal diagnosis and family counseling. This distinction is crucial for patient management and has genetic implications for relatives.

Oncotype DX risk scores are more influenced by estrogen-related genes, while other assays like MammaPrint are driven more by genes related to cell proliferation. This fundamental difference in their underlying biology can inform an oncologist's choice of which genomic test is most appropriate for a given patient's tumor.